Skip to main content
CMMB
NASDAQ Life Sciences

Chemomab Reports Positive Nebokitug Data, Extends Runway, Seeks Partners Amidst Financial Pressure

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.74
Mkt Cap
$12.515M
52W Low
$1.35
52W High
$5.88
52W Position info
29% above low
Off High info
70% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CMMB sits 29% above its 52-week low of $1.35.

Summary

Chemomab Therapeutics announced positive new clinical data for its lead asset, nebokitug, showing potential benefits for PSC patients with co-existing IBD, while also reporting Q1 2026 financial results that extend its cash runway through Q1 2027 as it pursues partnering options.


Key Events · Product Development and Regulatory · CMMB

  • Positive Clinical Data for Nebokitug

    New Phase 2 data presented at major medical meetings further confirms nebokitug's disease-modifying potential in PSC and suggests additional benefit for PSC patients with co-existing IBD, potentially expanding its market.

  • Extended Cash Runway

    Cash, cash equivalents, and short-term deposits totaled $8.0 million as of March 31, 2026, which is expected to fund operations through the end of the first quarter of 2027.

  • Strategic Partnering Efforts

    The company continues to advance multiple partnering options for nebokitug, a critical strategy given its financial position and the new clinical data.

  • Reduced Net Loss

    Net loss for Q1 2026 was $1.8 million, a decrease from $3.3 million in Q1 2025, primarily due to the winding down of Phase 2 SPRING trial activities and reduced R&D expenses.


Analysis · CMMB · Life Sciences

This filing provides new positive clinical data for nebokitug, particularly highlighting its potential benefit for Primary Sclerosing Cholangitis (PSC) patients with co-existing Inflammatory Bowel Disease (IBD). This expanded therapeutic potential could significantly enhance nebokitug's market attractiveness and is crucial for the company's ongoing efforts to secure strategic partnerships. While the company has extended its cash runway through Q1 2027, the financial position remains tight, especially following a recent 'going concern' warning and a proposal for massive share dilution. The positive clinical data is a critical development that could help mitigate these financial risks by making the asset more appealing to potential partners.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CMMB was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $1.35 to $5.88. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CMMB - Latest Insights

CMMB
Nov 10, 2026, 5:30 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.31 info
Change: -$0.035 (-3%) info
Market Cap: $9.492M info
CMMB
Nov 10, 2026, 5:26 PM EST
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.31 info
Change: -$0.035 (-3%) info
Market Cap: $9.492M info
CMMB
Oct 30, 2026, 4:32 PM EDT
Filing Type: DEFM14A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $1.31 info
Change: +$0.190 (+17%) info
Market Cap: $9.492M info
CMMB
Oct 19, 2026, 5:28 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.31 info
Change: +$0.120 (+10%) info
Market Cap: $9.492M info
CMMB
Sep 30, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.31 info
Change: +$0.120 (+10%) info
Market Cap: $9.492M info